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Determining Levers of Cost-effectiveness for Screening Infants at High Risk
for Peanut Sensitization Before Early Peanut Introduction
Matthew Greenhawt, MD, MBA, MSc; Marcus Shaker, MD, MSc

Abstract
IMPORTANCE Early peanut introduction reduces the risk of developing peanut allergy, especially in
high-risk infants. Current US recommendations endorse screening but are not cost-effective relative
to other international strategies.
OBJECTIVE To identify scenarios in which current early peanut introduction guidelines would be
cost-effective.

Key Points
Question Although the current US
policy of early peanut introduction is not
cost-effective compared with universal
introduction without screening, are
there variables and assumptions under
which this policy could be costeffective?

DESIGN, SETTING, AND PARTICIPANTS This simulation/cohort economic evaluation used

Findings In this simulation/cohort

microsimulations and cohort analyses in a Markov model to evaluate the cost-effectiveness of early

economic evaluation, screening high-

peanut introduction with and without peanut skin prick test (SPT) screening in high-risk infants

risk infants before peanut introduction

during an 80-year horizon from a societal perspective. Data were analyzed from April to May 2019.

was cost-effective at very high disutility
(76-148 days of life traded) for having

EXPOSURES High-risk infants with early-onset eczema and/or egg allergy underwent early peanut

an in-office index reaction or with

introduction with and without peanut SPT screening (100 000 infants per treatment strategy) using

greater than 36% baseline peanut

a dichotomous 8-mm SPT cutoff value (stipulated in the current US guideline).

allergy prevalence and peanut skin prick
test sensitivity of 0.85 and specificity

MAIN OUTCOMES AND MEASURES Cost, quality-adjusted life-years (QALYs), net monetary
benefit, peanut allergic reactions, severe allergic reactions, and deaths due to peanut allergy.

of 0.98.
Meaning These results suggest that
cost-effectiveness of the current US

RESULTS In the simulated cohort of 200 000 infants and using the base case during the model
horizon, a no-screening approach had lower mean (SD) costs ($13 449 [$38 163] vs $15 279
[$38 995]) and higher mean (SD) gain in QALYs (29.25 [3.28] vs 29.23 [3.30]) vs screening but
resulted in more allergic reactions (mean [SD], 1.07 [3.15] vs 1.01 [3.02]), severe allergic reactions
(mean [SD], 0.53 [1.66] vs 0.52 [1.62]), and anaphylaxis involving cardiorespiratory compromise
(mean [SD], 0.50 [1.59] vs 0.49 [1.47]) per individual. In deterministic SPT sensitivity analyses at

early peanut introduction policy
depends on a high disutility for having
an index peanut allergic reaction at
home, a high ambient prevalence of
peanut allergy, and very high sensitivity
and specificity of the skin prick test.

base-case sensitivity and specificity rates, screening could be cost-effective at a high disutility rate
(the negative effect of a food allergic reaction) (76-148 days of life traded) for an at-home vs in-clinic
reaction in combination with high baseline peanut allergy prevalence among infants at high risk for
peanut allergy and not yet exposed to peanuts. If an equivalent rate and disutility of accidental and
index anaphylaxis was assumed and the 8-mm SPT cutoff had 0.85 sensitivity and 0.98 specificity,

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

screening was cost-effective at a peanut allergy prevalence of 36%.
CONCLUSIONS AND RELEVANCE The results of this study suggest that the current screening
approach to early peanut introduction could be cost-effective at a particular health utility for an
in-clinic reaction, SPT sensitivity and specificity, and high baseline peanut allergy prevalence among
high-risk infants. However, such conditions are unlikely to be plausible to realistically achieve. Further
research is needed to define the health state utility associated with reaction location.
JAMA Network Open. 2019;2(12):e1918041. doi:10.1001/jamanetworkopen.2019.18041
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Introduction
Peanut allergy affects 1% to 4.5% of children, can potentially be severe, and is not readily outgrown
in most individuals.1 Moreover, although treatments are on the horizon, a cure remains elusive, and
management involves strict avoidance and anaphylaxis preparedness.2,3 For these reasons, peanut
allergy is associated with impaired quality of life and anxiety.4,5 Important advances have been made
regarding prevention of peanut allergy through deliberate early introduction, in particular targeting
populations of children at risk for developing peanut allergy, as demonstrated in the Learning Early
About Peanut Allergy (LEAP) trial in which a dramatic risk reduction was noted against developing
peanut allergy at 5 years of age through early peanut introduction at 4 to 11 months of life compared
with delayed introduction.6
The strength of these findings helped to reverse prior recommendations to avoid peanut in
infants and young children until 3 years of age and resulted in the recent National Institutes for
Allergy and Infectious Disease (NIAID) addendum guidelines that recommend early introduction to
prevent peanut allergy.7 This strategy was adopted in the United Kingdom, Canada, Australia, and
New Zealand, although the wording of the policy and the implementation of this guidance vary
among these nations. The United Kingdom, Australia, and New Zealand, and now the Canadian
Pediatric Society all recommend early peanut introduction at approximately 6 months of age (but not
before 4 months of age) without any prescreening and risk stratification.7-10 However, the NIAID
guidelines strongly recommend that high-risk infants (eg, those with severe eczema and/or egg
allergy) undergo peanut allergy testing at 4 to 6 months of age before having peanut introduced.
Infants demonstrating peanut skin prick test (SPT) sensitization ranging from 3 to 7 mm are
recommended to have in-clinic peanut introduction; those with sensitization of at least 8 mm are
diagnosed as having preexisting peanut allergy, and introduction is withheld. For lower-risk infants
(or infants not at risk), peanut introduction is advised as early as 6 months of age, without such
medicalization or screening, in accordance with family values and preferences7 (eTable in the
Supplement).
Although the NIAID strategy largely follows, with some extension, the parameters used in the
LEAP study, the necessity of medical screening before peanut introduction was never specifically
evaluated (because screening was not a randomized study variable) and can be questioned in light of
the differing international strategies chosen.11 Indeed, applying the NIAID criteria to the HealthNuts
population (an Australian population-level food allergy prevalence study in children aged 1 year),12
even if all infants with early-onset eczema and/or egg allergy were screened (approximately 16% of
all infants born each year), 23% of all children in this cohort diagnosed with peanut allergy would
have been missed. This raises questions about the sensitivity and specificity of these criteria as well
as their necessity given that most initial reactions to peanut were mild and a fatal index peanut
reaction has never been described.13
Moreover, in a recent cost-effectiveness model exploring the differing international
recommendations for how to implement early peanut introduction, the screening strategy
(irrespective of use of serologic evaluation or SPT) was dominated by a no-screen approach (eg,
screening resulted in higher costs and lower benefits). Screening led to greater overdiagnosis, which
attenuated the benefit of preventing a peanut index reaction.14 This overdiagnosis is a residual result
of using a skin test cutoff based on a probability for allergy (whereby some will be diagnosed without
ever eating and reacting to peanut), whereas if these individuals were allowed to ingest peanut, not
all of them would have a reaction per se. Cost-effectiveness of the recommendations may not affect
their implementation, because caregivers and physicians may still opt for care that is considered
wasteful or low value based on such findings. A limitation of the previous analysis14 was that it strictly
compared the approaches and did not explore all levers or pathways that may exist for the NIAID
recommendations to potentially be cost-effective. One particular lever of cost-effectiveness may be
the health utility surrounding the location where someone’s index reaction to peanut occurs. In the
case of early introduction, some families and health care professionals may differentially value or
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more strongly prefer a particular setting for where a first potentially severe index reaction
attributable to early peanut introduction occurs—in a clinic under medical supervision vs at home.15
Caregivers and health care professionals who place high value on avoiding an at-home index reaction
to peanut, whether mild or severe, and who would rather this reaction occur in a medically
supervised setting may strongly prefer the recommended screening approach with reflexive food
challenge for modest positive screening results (3- to 7-mm wheal of a peanut SPT), whereas those
who value this scenario less or have no preference may opt for at-home introduction. Such differing
valuation could drastically affect the cost-effectiveness of screening. Therefore, we undertook this
simulation and cost-effectiveness analysis to evaluate the optimal peanut introduction strategy for
high-risk infants in the setting of differential potential health utility for medically supervised vs
at-home index reactions to peanut.

Methods
This study was deemed exempt from institutional review board approval and informed consent by
the Colorado Multiple Institutional Review Board of the University of Colorado because it evaluated
simulated cohorts of infants at risk for peanut allergy with the use of aggregate published data as
model inputs and did not qualify as human research. The analysis conformed to the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) reporting guideline.16

Decision Model
Microsimulations (100 000 per strategy) and cohort analyses were used to evaluate a Markov model
of early peanut introduction with and without peanut SPT screening in infants deemed to be at high
risk for peanut allergy development per the NIAID guidelines (those with early-onset eczema and/or
egg allergy) during an extended 80-year horizon from a societal perspective. An extended time
horizon was used to better understand the long-term societal outcomes of screening decisions made
during infancy in an allergy considered to be lifelong for most patients.
Infants randomized to screening received a peanut SPT with an initial dichotomous outcome
defined at 8 mm, the cutoff in the NIAID guidelines at which an infant is recommended to be
diagnosed as allergic and not offered early introduction. A positive test result was considered to be a
wheal of at least 8 mm; a negative test result, a wheal of less than 8 mm. Children with an SPT result
of 3 to 7 mm underwent supervised peanut challenge in an allergy clinic, and those with an SPT result
of less than 3 mm underwent home peanut introduction, per NIAID guidelines.7,14 Figure 1 depicts
the following outcomes of screening at the 8-mm threshold: (1) true-positive (sensitized and
allergic), (2) false-positive (sensitized but not truly allergic; however, not challenged to determine
this), (3) true-negative (not sensitized and tolerant), and (4) false-negative (skin test <8 mm but
allergic). Sensitivity of peanut SPT (ⱖ8 mm) was derived from the HealthNuts cohort and modeled
at 0.54 with a specificity of 0.98, the population from which the NIAID guideline cutoff value was
obtained.17 In the base-case model, a false-positive test result (SPT ⱖ8 mm) led to a diagnosis of
peanut allergy without challenge (as per NIAID guidelines)7; however, infants with a false-positive
SPT result did not assume the risks of allergic reactions from accidental peanut ingestion. Children
with true-positive test results (SPT ⱖ8 mm) avoided peanut and entered the natural history model of
peanut allergy, whereas those with false-positive results avoiding peanut entered a natural history
model that included avoidance under a peanut allergy health state utility but also included the
possibility that natural tolerance would be inadvertently discovered. Children with false-negative SPT
results were presumed to discover (through supervised or home challenge) that they were allergic
within the initial year of the model cycle and subsequently entered the peanut allergy health state.
Models were evaluated for cost, quality-adjusted life-years (QALYs), net monetary benefit, peanut
allergic reactions, severe reactions, and deaths due to peanut allergy. Model trackers were used to
evaluate episodes of severe allergic reactions and fatalities.12,18-21 A threshold for cost-effective care
was set at $100 000/QALY.22
JAMA Network Open. 2019;2(12):e1918041. doi:10.1001/jamanetworkopen.2019.18041 (Reprinted)
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Probabilities
Model inputs12,13,17,19-21,23-30 shown in Table 1 included a 14% prevalence of peanut allergy in the highrisk infants during infancy.13,14 Age-adjusted all-cause mortality was incorporated with 2013 US life
tables.23 The accidental rate of peanut exposure was 11.7% per year (range, 5.0%-45.0%), with
severe allergic reactions occurring in 52.0% of accidental reactions (range, 1.0%-55.0%). Severe
reactions on first exposure to peanut occurred in 30.5% of patients (range, 5.0%-55.0%), with 8.3%
of index reactions involving respiratory or cardiovascular compromise.12,20 Hospitalization was
required in 35.0% of patients experiencing severe allergic reactions (range, 5.0%-45.0%).21 Deaths
due to food allergy were included (aged 0-19 years, 3.25 [95% CI, 1.73-6.10] per 1 million
person-years; aged ⱖ20 years, 1.81 [95% CI, 0.94-3.45] per 1 million person-years).19 A 20% rate of
discovery of overdiagnosis (range, 5%-80%) was modeled during the first 20 years of the simulation.

Figure 1. Outcomes of Peanut Allergy Screening and Decision Trees of Diagnoses
A Decision tree

To screen or not to screen?

B

True positive

False positive

True negative

False negative

Peanut allergy
correctly
diagnosed

Overdiagnosis

Peanut allergy
excluded

Reaction on
exposure

Correct diagnosis
Survive
Hospitalization
Fatal reaction
Severe allergic reaction
Allergic reaction from
accidental exposure

Survive
No hospitalization
Fatal reaction

Continued allergy

No severe allergic reaction
No reaction from
accidental exposure

Spontaneous tolerance

C

Peanut allergy
Deceased
Peanut allergy
Deceased

Peanut allergy

Peanut allergy

Resolved peanut allergy

False-positive diagnosis
Discovery of tolerance

No peanut allergy

Accidental exposure
Continued allergy

No discovery of tolerance
No accidental exposure

Spontaneous tolerance

False-positive peanut allergy diagnosis

False-positive peanut allergy diagnosis

Resolved peanut allergy

D False-negative diagnosis

Survive
Hospitalization
Fatal reaction
Severe allergic reaction
Survive
No hospitalization
Fatal reaction
No severe allergic reaction

Clone 1: peanut allergy natural history
Deceased
Clone 1: peanut allergy natural history
Deceased

Peanut allergy
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Costs
Costs of living with peanut allergy were expressed in 2018 dollars and discounted at 3% per annum.
Job-related opportunity costs of caregivers were estimated at $2597 per year.24-26 Direct costs
included allergist, primary health care professional, nutritionist, and alternative health care
professional visits, self-injectable epinephrine, groceries, and anaphylaxis management (emergency
department care and hospitalization), which were obtained from previously published
analyses.27-29,31

Table 1. Simulation Model Inputs
Variable

Model Reference

Source

US life table

National Vital Statistics Reports, April 2017

Arias et al,23 2017

Testing characteristics

Peters et al,17 2013
SPT (8-mm cutoff): sensitivity, 0.54 (range,
0.50 to 0.98); specificity, 0.98 (range 0.60 to
0.99)

Deaths due to food allergy

Aged 0-19 y, 3.25 (95% CI, 1.73 to 6.10) per
1 million person-years (sensitivity, 0.30 to
30.00); aged ≥20 y, 1.81 (95% CI, 0.94 to
3.45) per 1 million person-years (sensitivity,
1.81 to 18.10)

Umasunthar et al,19 2013

Rate of accidental peanut exposure
and symptoms in persons with
peanut allergy

11.7%/y (sensitivity, 5.0% to 45.0%)

Vander Leek et al,20 2000

Rate of severe allergic reaction in
persons with peanut allergy per
year

Accidental: 52.0% (sensitivity, 1.0% to
55.0%); index introduction: 30.5%
(sensitivity, 5.0% to 55.0%)

Vander Leek et al,20 2000;
Osborne et al,12 2011

Hospitalization rate after ED visit
for severe allergic reaction

35.0% (sensitivity, 5.0% to 45.0%)

Robinson et al,21 2017

Cost of primary health care visits
per year

$100 (Sensitivity, $94 to $105)

Gupta et al,27 2013; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Cost of allergist visits for food
allergy

Initial consultation for testing: $687
(sensitivity, $500 to $1200); oral food
challenge; $124 (sensitivity, $100 to $600);
annual follow-up visits: $149 (sensitivity,
$140 to $152)

Gupta et al,27 2013; CMS,25
2017; Dartmouth-Hitchcock,26
2017; US Department of Labor,
Bureau of Labor Statistics,24
2017

Cost of nutritionist visits for food
allergy per year

$17 (Sensitivity, $15 to $18)

Gupta et al,27 2013; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Cost of alternative health care
professional visits for food allergy
per year

$25 (Sensitivity, $22 to $27)

Gupta et al,27 2013; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Incremental cost of groceries
(living with food allergy) per year

$310 (Sensitivity, $290 to $330)

Gupta et al,27 2013; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Costs of job-related opportunity
due to food allergy per year

$2597 (Sensitivity, $0 to $2697)

Gupta et al,27 2013; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Cost of personal epinephrine
autoinjector

$715 (Sensitivity, $50 to $1000)

Shaker et al,29 2017; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Cost of skin test

$24 (Sensitivity, $10 to $40)

CMS,25 2017

Cost of hospitalization

$5899 (95% CI, $5732 to $6066)

Patel et al,28 2011; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Cost of ED visit

$691 (95% CI, $689 to $693)

Patel et al,28 2011; US
Department of Labor, Bureau of
Labor Statistics,24 2017

Negative health state influence for
food allergy and anaphylaxis

−0.09 (Sensitivity, −0.05 to −0.11)

Carroll and Downs,30 2009

Cycle length

1y

NA

Peanut allergy pretest probability

14.0% (Sensitivity, 14.0% to 40.0%)

Koplin et al,13 2016

Annual discount rate

0.03 (Sensitivity, 0 to 0.05)

NA

Probability of identifying falsepositive test result during model
horizon

20.0% (Sensitivity, 5.0% to 80.0%)

NA
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Health State Utilities
Quality-adjusted life-years were derived from health state utilities for patients living with peanut
allergies, discounted at 3% per annum. Carroll and Downs30 assessed health state utility values by
standard gamble and time trade-off in 4016 parents or guardians of at least 1 child younger than 18
years recruited at random from multiple sources. Health state utility values for moderate and severe
allergic reactions were 0.93 for standard gamble and 0.91 for time trade-off. The disutility of an
allergic reaction was −0.09.30 Health state disutility represents a negative health detriment assigned
for a particular event relative to the condition of interest. In this case, the disutility translates to
approximately 33 days of life in a single year being traded to avoid having an allergic reaction.
We used SDs to describe probabilistic determination of uncertainty associated with variation in
event rates resulting from linked probabilities of individual outcomes during Monte Carlo simulation.
In addition, for probabilistic sensitivity analysis, triangular distributions (minimal, maximal, and mode
values specified) were evaluated simultaneously to evaluate certainty of findings.

Statistical Analysis
Data were analyzed from April to May 2019. Univariate deterministic sensitivity analyses were
performed on individual variables. Multivariate probabilistic sensitivity analyses (n = 1000) with
triangular modal distributions were performed across upper and lower bounds of plausible ranges.
Sensitivity analyses included SPT sensitivity ranges from 0.70 to 0.98 and specificities of 0.33 to
0.99, higher baseline prevalence rates of peanut allergy among high-risk infants undergoing early
peanut introduction, lower chances of discovering false-positive diagnoses, and mortality rates
increased to 10-fold in the base-case risk.17 Accidental annual peanut reaction rates were modeled to
a lower limit of 1%, with as many as 55% of index reactions resulting in anaphylaxis. Sensitivity
analyses excluding job-related opportunity costs and evaluating epinephrine autoinjector costs at
$50 per year were also performed.

Results
The simulated population included 100 000 infants with and 100 000 infants without the SPT
screening. During the 80-year time horizon, a no-screening approach dominated SPT screening in
high-risk infants for costs (mean [SD], $13 449 [$38 163] vs $15 279 [$38 995]) and QALYs (mean
[SD], 29.25 [3.28] vs 29.23 [3.30]). As shown in Table 2, when compared with screening, a
no-screening approach resulted in slightly higher rates of allergic reactions (mean [SD], 1.07 [3.15] vs
1.01 [3.02]), severe allergic reactions (mean [SD], 0.53 [1.66] vs 0.52 [1.62]), and accidental
anaphylaxis together with index reactions that included respiratory or cardiovascular compromise
(mean [SD], 0.50 [1.59] vs 0.49 [1.47]) per patient at risk. However, rates of deaths due to food

Table 2. Comparison of Screening vs No Screening Approaches
Mean (SD)

Effectiveness,
QALY

NMB, $

Food Allergic
Reactions,
No./Individual

Severe Allergic
Reactions,
No./Individuala

Deaths
Due to
Food
Allergy,
Rate/
Patient

Therapy

Cost, $

No
screening

13 449 29.25
(38 163) (3.28)

2 912 020
(338 854)

1.07
(3.15)

0.53
(1.66)

SPT
screening

15 279 29.23
(38 995) (3.30)

2 908 022
(342 598)

1.01
(3.02)

0.52
(1.62)

Infants,
No.

Incremental
Cost, $

Incremental
Effectiveness

ICER

Peanut
Allergy at
Conclusion
of Model, %

0.00002
(0.0045)

100 000

NA

0.02

NA

6.3

0.00002
(0.0045)

100 000

$1830

NA

Dominated

6.5

Abbreviations: ICER, incremental cost-effectiveness ratio; NA, not applicable; NMB, net
monetary benefit; QALY, quality-adjusted life-year; SPT, skin prick test.
a

When inclusive of only accidental anaphylaxis together with index reactions, including
respiratory or cardiovascular compromise, the mean (SD) for no screening vs screening
was 0.50 (1.59) vs 0.49 (1.47).
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allergy were similar (and rare). Skin testing led to peanut allergy diagnosis in 6.5% of the screening
cohort vs 6.3% of participants in the nonscreening cohort as the model concluded. When modeling
the possible protective benefit of screening against an index reaction–associated peanut fatality, a
no-screening approach continued to dominate the analyses, even assuming as much as a 1000-fold
protection against fatality on the index ingestion associated with screening (screening incremental
cost, $1532; effectiveness, −0.018 in the cohort analysis).

Sensitivity Analyses
Because screening may incorporate variations in care that are sensitive to patient preference,
additional analyses explored differential caregiver health utility and disutility. In deterministic
sensitivity analyses at base-case sensitivity and specificity rates, SPT could be cost-effective
(willingness to pay, $100 000/QALY) when applying a very high rate of disutility for a home reaction
vs an in-clinic index reaction, in combination with a very high baseline peanut allergy prevalence in
the high-risk infant with no peanut exposure (which exceeded the base-case utility difference for
index in-clinic vs at-home anaphylaxis), and this interaction of these levers is demonstrated in
Figure 2. We also considered the threshold for test sensitivity and specificity at which this analysis
could be cost-effective. If an equivalent rate and disutility of accidental and index anaphylaxis was
assumed with an 8-mm SPT sensitivity of 0.85 and specificity of 0.98, the screening approach
became cost-effective at a peanut allergy prevalence of 36% (eFigure 1 in the Supplement).
Additional deterministic analyses did not demonstrate cost-effective care for a screening approach
(Figure 3). In probabilistic sensitivity analysis during a 20-year time horizon (n = 10 000), a
no-screen approach was the optimal strategy in 99.9% at a willingness to pay of $100 000/QALY
(eFigure 2 in the Supplement).

Discussion
The previous analysis by Shaker et al14 comparing the US, UK, and Australia and New Zealand
approaches calculated the cost to prevent a single case of a severe peanut allergic reaction under the
pathway recommended by addendum 1 in the NIAID guidelines to be approximately US $101 963.
Despite the lack of benefit, such a decision to screen may be preference sensitive. In a 2018
nationally representative survey of expecting parents (n = 1000) and new caregivers of infants
(n = 1000),15 61% had no or minimal concern for their child developing a food allergy, 54% thought
early introduction mattered in terms of preventing food allergy development, 31% were willing to
introduce peanut before 6 months of age, and 51% were unwilling to allow in-office risk assessments
of peanut allergy (eg, allergy testing or oral challenge) before 11 months of age. Although this study
was not designed as a formal preference-elicitation study and was performed at the beginning of the

Figure 2. Deterministic Sensitivity Analyses
–0.090

Anaphylaxis Differential Disutility

No screening
Skin prick testing
–0.193

–0.295

–0.398

–0.500
0.14

0.21

0.27

0.34

0.40

Peanut Allergy Prevalence
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life cycle of the NIAID addendum guidelines, this population was representative of caregivers and
family potentially having to make such a choice and infers that differential preference may exist
regarding early peanut introduction.
This present analysis confirms previous observations that screening high-risk infants for peanut
allergy is not cost-effective through a different model incorporating a longer time horizon and the
potential for spontaneous discovery of false-positive test results. Given that change to this policy is
unlikely, we took a novel approach of identifying key levers that could influence the costeffectiveness of the existing NIAID policy, albeit with a narrow potential (and arguably an infeasible
one given the specifications of the identified levers).14 These levers are a very high prevalence of
preexisting peanut allergy in the infants undergoing early introduction, a high disutility for having an
at-home index reaction, and enhanced SPT accuracy. Under most assumptions, even when
differential in-clinic vs at-home anaphylaxis disutility is modeled, false-positive diagnoses are not
subjected to ongoing risks of true peanut allergy, and spontaneous discovery of overdiagnosis is
considered, the burden imposed by screening SPT simply overshadows a no-screening approach in
terms of cost and effectiveness assessed by QALYs. In the present model, rates of anaphylaxis
occurring with no screening being performed are marginally greater at a mean (SD) of 0.50 (1.59) vs
0.49 (1.47), and although this difference is not significant, this finding may reflect the current
paradigm of advising that infants who are highly sensitized to peanut and have strong positive test
results not be offered the opportunity to establish oral tolerance to prevent the risk that they may
react at ingestion.14,32 However, this approach has not actually proven to be a shared decision
consistent with caregiver (as opposed to health care professional) values. In actuality, it may be more
accurate to assume that without being given any other option, such children with strong peanut
sensitization are highly likely to develop peanut allergy if not offered peanut in the first year of life, as
evidenced by the data (and secondary analysis data) from the LEAP study.11

Figure 3. Tornado Diagram of Incremental Net Monetary Benefit (NMB)
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A large contributor to the poor cost-effectiveness of the screening approach relates to the poor
accuracy of peanut allergy diagnostic test results in children who have not directly ingested peanut
and developed symptoms of an allergic reaction.33,34 For this reason, multiple past food allergy
guidelines in the United States and elsewhere have urged caution in testing individuals who have not
ever eaten a food before, a situation representing exceptionally low pretest probability at worst and
marginal pretest probability (which was elevated to marginal through severe eczema and/or egg
allergy as factors that may increase the odds of someone having peanut allergy compared with the
general population) at best.1,35
An optimal screening test should maximize the ability to accurately identify disease that would
lead to harm if not otherwise diagnosed early (eg, test sensitivity), because of adverse consequences
due to the natural history of the disease or because early management resulting from identification
can prevent likely complications of the disease, while minimizing potential false-positive diagnoses
and the resulting harm from managing a condition that is not actually present (eg, test specificity).
However, it is not clear that such situations exist in the realm of food allergy screening before
introduction, given that the test precision is imperfect (the test is most interpretable when results are
negative and is difficult to interpret when results are positive, particularly at a 3-mm cutoff) and
carries significant risk of false-positive results. Even when a patient is accurately diagnosed with
peanut allergy early, no treatment (and certainly no cure) is available yet (nor will be available until
the child is 4 years of age).2 Thus, early diagnosis may prevent an index reaction (including a
potentially severe one) under certain circumstances as the only tangible benefit and may identify
someone for future therapy, but otherwise, early diagnosis increases one’s life span with peanut
allergy and adds time under which poor quality of life may develop as a realistic detriment. The
advent of an available peanut allergy therapy in younger children might increase the value of peanut
allergy screening.
To our knowledge, no published or anecdotal reports exist of deaths due to peanut anaphylaxis
during infancy related to early introduction of a small amount of peanut protein (even in an infant
considered at high risk for peanut introduction). With an increase in early introduction, ongoing
surveillance of fatal food reactions during infancy will be important to continue to evaluate the safety
of this practice. In the HealthNuts study, although anaphylaxis rarely occurred, most reactions were
mild and cutaneous.12 A similar finding was noted in LEAP, although the trial was right censored from
challenge-proven outcomes at an SPT result of 5 mm, as well as in the other early introduction
studies.6 Most importantly, no data are available to suggest that death due to food allergy is more
likely in this age than any other age.36 One potential approach is to presume that this is a preferencesensitive choice, develop a decision aid, and provide families with a clear understanding of risks and
benefits of each approach that allows them to make the best decision for themselves. Although this
will not change the fact that, when viewed through an economic lens, peanut allergy screening for
early introduction is not cost-effective, it may help offset some potentially low-value care if parents
can be given more options than the current NIAID guidelines suggest.

Limitations
This analysis is limited given that it is a simulation reliant on the quality of its inputs, which in this case
come from the LEAP and HealthNuts cohorts. Because those studies were not conducted in a US
population, there could be difficulty with generalizability; nonetheless, they represent the most
robust and reasonable inputs for this model.6,12,13 In addition, the precise health utilities for peanut
allergy, early introduction, or preference for home vs supervised initial reactions are unknown and
need to be established. We explored levers that we believed might be amenable to change, but there
could be other levers that we did not explore. We did not include risks of motor vehicle collision
fatality associated with transportation for allergy evaluations, which could in fact greatly overshadow
any screening-associated risk reduction for death due to anaphylaxis.36-38 Also, as was noted in the
previous analysis by Shaker et al,14 we did not model wait lists for health care professionals and
reduced access as factors that could affect decision-making and the ability to receive timely care.
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Conclusions
In this study, screening for peanut sensitization in high-risk infants and presumptively diagnosing the
child with a peanut allergy based on large SPT result size or only providing the option for in-clinic
introduction for those with small- to moderate-size SPT results was not found to be cost-effective
compared with the general permissive strategy of recommending early introduction at home without
any assessment. However, it appears that this strategy could be cost-effective if caregivers have a
strong health utility for having an index reaction occur under medical supervision, with a very
accurate test result, or at a very high rate of ambient preexisting peanut allergy before early
introduction occurs. Further research is needed to better define these key attributes, and presuming
differential health utility exists for where caregivers prefer index reactions to occur, a formal decision
aid could be of considerable use to help caregivers and health care professionals engage in shared
decision-making to facilitate early peanut introduction.
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